Eligible Registrants – AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

Novel Rational Checkpoint Inhibitors

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 9 of 9
Introduction
Silvia C Formenti
Weill Cornell Medical College, New York, NY, United States
from AACR Annual Meeting 2019 on April 2, 2019 10:30 AM-12:45 PM
Neoadjuvant immuno-radiotherapy (NIRT) in head and neck cancer: Phase I/Ib study of combined PD-1/SBRT prior to surgical resection
Rom Leidner
EACRI - Providence Cancer Center, Portland, OR, United States
from AACR Annual Meeting 2019 on April 2, 2019 10:30 AM-12:45 PM
Discussant
Christine H Chung
Moffitt Cancer Center, Tampa, FL, United States
from AACR Annual Meeting 2019 on April 2, 2019 10:30 AM-12:45 PM
Phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies
Giuseppe Curigliano
Istituto Europeo di Oncologia IRCCS, Milan, Italy
from AACR Annual Meeting 2019 on April 2, 2019 10:30 AM-12:45 PM
Discussant
David S Hong
UT MD Anderson Cancer Ctr., Houston, TX, United States
from AACR Annual Meeting 2019 on April 2, 2019 10:30 AM-12:45 PM
Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial
Alexander E Perl
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, United States
from AACR Annual Meeting 2019 on April 2, 2019 10:30 AM-12:45 PM
Discussant
Tapan M. Kadia
UT MD Anderson Cancer Ctr., Houston, TX, United States
from AACR Annual Meeting 2019 on April 2, 2019 10:30 AM-12:45 PM
Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (telomelysin) with radiotherapy in esophageal cancer patients unfit for standard treatments
Toshiyoshi Fujiwara
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
from AACR Annual Meeting 2019 on April 2, 2019 10:30 AM-12:45 PM
Discussant
Geoffrey Y Ku
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2019 on April 2, 2019 10:30 AM-12:45 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 9 of 9